Full Press Release Details
Forward Looking Statements
This presentation contains certain statements that constitute forward-looking statements within the
meaning of the federal securities laws. Statements that are not historical facts, including statements
about our beliefs and expectations, are forward-looking statements. These statements are not
guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to
predict. The forward looking statements in this presentation include statements about our business,
including commercialization plans and potential markets for our products and product candidates,
clinical trials, potential indications for our product candidates, development timelines, regulatory
timelines and future events that have not yet occurred. Pharmaceutical and medical device
development inherently involves significant risks and uncertainties, including the risks outlined in "Risk
Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March 27, 2013 and in "Risk Factors" in our Quarterly Reports on Form 10-Q filed with the Securities
and Exchange Commission on May 15 and August 14, 2013. Our actual results may differ materially
from our expectations due to these risks and uncertainties, including, but not limited to, our
dependence on the success of our lead product candidate, and factors relating to commercialization
and regulatory approval thereof, ability to raise sufficient capital, retaining our stock's listing on the
NYSE MKT, research and development activities, intellectual property protection, competition,
industry environment, and other matters. Any forward-looking statements included in this presentation
are based on information available to us on the date of this presentation. We undertake no obligation
to update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise.
CorMedix: A Catheter Care Company
Successful launch in Germany and Austria
Experienced sales team targets early
Increase healthcare provider awareness
Negotiate Partner Arrangements
Position Neutrolin strategically
Understand payer reimbursement policies
Expansion into oncology, ICU, Total
Parenteral Nutrition, and peritoneal
Submission of required data to TUV
Develop target list of physicians and
expand the sales force
Identify and prioritize key countries
Identify best sales partners in key
Screening/due diligence / deal
negotiations conducted with
country and regional specific
Monitor product positioning and
coordinate manufacturing capacity
Potential Opportunity for Consideration:
U.S. FDA discussions (pre-IND meeting, timelines)
Clinical trial requirements by FDA
Patient population size
Clinical trial execution decision
Go alone if sufficient internal funding
Business Development to Target Countries with
High Catheter Use and Favorable Reimbursement
Major Countries: U.S., Japan,
China, Brazil, Germany, Canada
Source: Derived from USRDS, 2011, and Dialysis Outcomes and Practice Pattern Study (DOPPS) Annual
Report 2010, and Canadian Institute for Health Information, Canadian Organ Replacement Registry
Process in Place to Select Best Sales Partner
Large Worldwide Hemodialysis Opportunity
European Union Sales Partnerships:
91,000 hemodialysis catheter patients
U.S. Clinical Development Funding and Sales Partnerships
104,000 hemodialysis catheter patients
Top 5 Hemodialysis markets: U.S., Japan, China, Brazil, Germany.
Source: Derived from USRDS, 2011, and Grassman, Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and
Dialysis Outcomes and Practice Pattern Study (DOPPS) Annual Report 2010, CorMedix estimates
Asia/Middle East/North and South America Sales Partnerships
106,000 hemodialysis catheter patients
China, Japan, Korea, Saudi Arabia, Brazil, Canada
Opportunity to Grow with Label Expansion into other
Catheter Applications
European Union Sales Partnerships:
145,600 catheter patients
U.S. Clinical Development Funding and Sales Partnerships
124,800 catheter patients
Other catheter applications: chemotherapy, intensive care, total parenteral nutrition.
Source: CorMedix estimates based on hemodialysis catheter patients derived from USRDS, 2011, and Grassman,
Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and Dialysis Outcomes and Practice Pattern Study (DOPPS)
Asia/Middle East/North and South America Sales Partnerships
106,000 catheter patients
China, Japan, Korea, Saudi Arabia, Brazil, Canada
Significant Near Term Hemodialysis Opportunity in E.U.
Initially CorMedix will target the Hemodialysis market:
E.U. : 91,000 hemodialysis catheter patients
These patients represent ~14.2 million HD sessions per year
(91,000 HD catheter patients * 3 weekly dialysis sessions/week * 52 weeks per year = 14.2 million)
Potential Hemodialysis Market Size in E.U. :
USD $40 - $80 million
Source: Derived from USRDS, 2011, and Grassman, Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and
Dialysis Outcomes and Practice Pattern Study (DOPPS)
..and Even Greater Opportunity in the Long Term
with Other Key Countries and an Expanded Label
Hemodialysis and Expanded Label market:
E.U.: 236,600 catheter patients
Other Key Countries: 212,000 catheter patients
Long Term Potential Market Size in E.U. and Other Key Countries
for Hemodialysis and Expanded Label:
USD $180 - $340 million
Top 5 Hemodialysis markets: U.S., Japan, China, Brazil, Germany.
Source: Derived from USRDS, 2011, and Grassman, Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and
Dialysis Outcomes and Practice Pattern Study (DOPPS)
Option to Enter the United States with Strategic
Partnerships or Internal Funding
U.S. Hemodialysis and Expanded Label market:
228,800 catheter patients